ENPP2 and digestive system neoplasm: An ATX inhibitor, IOA-289, has recently entered a clinical trial for individuals with PDAC (NCT05586516) based on promising preclinical results in gastrointestinal tumor models21–23, and a deeper understanding of ATX function in PDAC may inform translational efforts.